Bill Snyder

October 18, 2021

Nominations being accepted for 2022 Vanderbilt Prize

Nominations for the 2022 Vanderbilt Prize in Biomedical Science are now being accepted.

By Bill Snyder
Stomach
October 14, 2021

New marker for metaplasia

A protein that transports water, called aquaporin 5, is expressed by cells undergoing changes that may increase risk for gastric cancer development, Vanderbilt researchers discovered.

By Bill Snyder
October 14, 2021

STAR Clinical Research Network to receive major grant renewal

Vanderbilt’s STAR Clinical Research Network has been approved for an additional $8.9 million in funding from the Patient-Centered Outcomes Research Institute (PCORI) to support its efforts to improve health care throughout the Southeast and across the United States.

By Bill Snyder
October 7, 2021

Study seeks to improve kidney transplant outcomes among Black patients

By Bill Snyder
October 7, 2021

Nominations sought for VUSM Research Staff Awards

By Bill Snyder
October 5, 2021

AstraZeneca seeks emergency approval for COVID-19 antibodies isolated at VUMC

Biopharmaceutical company AstraZeneca has requested emergency use authorization (EUA) from the U.S. Food and Drug Administration for a long-acting antibody combination originally developed at Vanderbilt University Medical Center to protect against COVID-19.

By Bill Snyder
October 1, 2021

VUMC research contributed to first COVID-19 pill now under review

Vanderbilt research helped allow pharmaceutical giant Merck & Co. to authorization for the first oral antiviral pill to treat COVID-19.
By Bill Snyder
September 29, 2021

Neurotransmitter transporters expert Amara set for Oct. 7 Discovery Lecture

Susan Amara, PhD, scientific director of the Intramural Research Program at the NIMH and an expert on the biology of neurotransmitter transporters, will deliver Vanderbilt's next Discovery Lecture via Zoom at 4 p.m., Thursday, Oct. 7.
By Bill Snyder
September 22, 2021

“Ultra-potent” antibody against COVID-19 variants isolated at VUMC

A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.
By Bill Snyder
September 16, 2021

VUMC team to test personalized acute heart failure treatment

Researchers at Vanderbilt have been awarded a five-year, $4 million federal grant to test whether a personalized medicine strategy will improve outcomes for patients hospitalized with acute heart failure.
By Bill Snyder
September 16, 2021

Chung receives early investigator award from ASCPT

Vanderbilt's Cecilia Chung, MD, MPH, has received the 2022 Leon I. Goldberg Early Investigator Award from the American Society of Clinical Pharmacology and Therapeutics (ASCPT).
By Bill Snyder
September 16, 2021

‘Pre-conditioning’ restores immune tolerance

A treatment targeting T-cell metabolism could reinvigorate immune tolerance mechanisms to combat autoimmune disease and transplant rejection, Vanderbilt researchers discovered.
By Bill Snyder